Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Challenges and opportunities for medications development in alcoholism: An international perspective on collaborations between academia and industry

Johnson, B A ; Mann, K ; Willenbring, M L ; Litten, R Z ; Swift, R M ; Lesch, O M and Berglund, Mats LU (2005) In Alcoholism: Clinical and Experimental Research 29(8). p.1528-1540
Abstract
This article represents the proceedings of a symposium presented at the 12th Congress of the International Society for Biomedical Research on Alcoholism held in Heidelberg/Mannheim, Germany, on September 30, 2004. The organizers and cochairs were Bankole A. Johnson, DSc, MD, PhD, and Karl Mann, MD. The presentations included the following: (1) A Perspective from Academia, by Bankole A. Johnson, DSc, MD, PhD; (2) A Perspective from NIAAA, by Mark L. Willenbring, MD; (3) A Perspective from US Clinical Practice, by Robert M. Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD.
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
antagonist, cannabinoid, acamprosate, naltrexone, ondansetron, alcohol, topiramate
in
Alcoholism: Clinical and Experimental Research
volume
29
issue
8
pages
1528 - 1540
publisher
Wiley-Blackwell
external identifiers
  • wos:000231767900021
  • pmid:16156050
  • scopus:24144470778
ISSN
0145-6008
DOI
10.1097/01.alc.0000174690.63787.fc
language
English
LU publication?
yes
id
317c4acc-e7cc-4d26-9848-bd0f103d83e1 (old id 225115)
date added to LUP
2016-04-01 12:17:07
date last changed
2022-01-27 01:28:36
@article{317c4acc-e7cc-4d26-9848-bd0f103d83e1,
  abstract     = {{This article represents the proceedings of a symposium presented at the 12th Congress of the International Society for Biomedical Research on Alcoholism held in Heidelberg/Mannheim, Germany, on September 30, 2004. The organizers and cochairs were Bankole A. Johnson, DSc, MD, PhD, and Karl Mann, MD. The presentations included the following: (1) A Perspective from Academia, by Bankole A. Johnson, DSc, MD, PhD; (2) A Perspective from NIAAA, by Mark L. Willenbring, MD; (3) A Perspective from US Clinical Practice, by Robert M. Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD.}},
  author       = {{Johnson, B A and Mann, K and Willenbring, M L and Litten, R Z and Swift, R M and Lesch, O M and Berglund, Mats}},
  issn         = {{0145-6008}},
  keywords     = {{antagonist; cannabinoid; acamprosate; naltrexone; ondansetron; alcohol; topiramate}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{1528--1540}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Alcoholism: Clinical and Experimental Research}},
  title        = {{Challenges and opportunities for medications development in alcoholism: An international perspective on collaborations between academia and industry}},
  url          = {{http://dx.doi.org/10.1097/01.alc.0000174690.63787.fc}},
  doi          = {{10.1097/01.alc.0000174690.63787.fc}},
  volume       = {{29}},
  year         = {{2005}},
}